Work

Folate-Functionalized PAMAM–Nanodiamond Conjugates for Sustained pH-Dependent Cabazitaxel Release and Enhanced Cytotoxicity in Prostate Cancer Cells

Year: 2026
Type: article
Abstract: Cabazitaxel (CTX) is an effective chemotherapeutic agent for advanced prostate cancer, but limited aqueous solubility and systemic toxicity motivate alternative delivery strategies. Herein, we developed a folate receptor-targeted nanodiamond-based nanoconjugate (ND-PAMAM-FA-CTX) for selective and controlled drug delivery. Cabazitaxel was first converted to CTX-hemisuccinate and subsequently conjugated to a fourth-generation polyamidoamine (PAMAM) dendrimer along with folic acid (FA), followed by covalent attachment to nanodiamonds (NDs). Comprehensive physicochemical characterization confirmed the successful construction of the nanoconjugate while preserving the structural integrity of the nanodiamond core. The resulting platform exhibited high CTX-loading capacity and a sustained, pH-responsive drug-release profile, with enhanced release under acidic conditions relevant to the tumor microenvironment. The drug-free carrier showed excellent biocompatibility, whereas ND-PAMAM-FA-CTX demonstrated superior anticancer activity against folate receptor (FAR)-overexpressing PC3 prostate cancer cells compared with free CTX and nontargeted controls. Flow cytometry and confocal microscopy revealed significantly enhanced cellular uptake mediated by folate receptor-dependent endocytosis, which was further confirmed through competitive inhibition studies using free folic acid. Moreover, ND-PAMAM-FA-CTX exhibited a low nanomolar IC50 value (∼5 nM) and markedly suppressed PC3 cell migration. Overall, these findings demonstrate that ND-PAMAM-FA-CTX is a promising targeted nanotherapeutic platform that combines selective cellular delivery and controlled drug release with enhanced efficacy, offering potential for future targeted chemotherapy applications.
Source: ACS Omega
Language: English
Subfield: Biomaterials
Open Access status: gold
Estimated APC paid: $1,935
OpenAlex ID: W7234161674
FWCI:
Cites: 50
Cited by:
Related to: 10